FDA Inspection 1232144 — Lonza Biologics, Inc.
The FDA completed an inspection of Lonza Biologics, Inc. on March 7, 2024 in Portsmouth, NH. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Biologics.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- March 7, 2024
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Portsmouth, NH (United States)